[Effect of human recombinant-gamma interferon on the immune function of peripheral blood lymphocytes in cancer patients]. 1986

J Yamada, and N Tanaka, and S Kamitani, and K Goto, and J Gangi, and K Orita

We administered recombinant gamma-interferon (ReIFN-gamma) daily to 7 cancer patients, and the effect on the immune function of peripheral blood lymphocytes was studied. Following the administration of ReIFN-gamma, no characteristic changes were observed in leukocyte count, lymphocyte count, OKT4/OKT8 or Leu 7. Natural killer cell cytotoxicity was augmented in all cases from the first week of administration and retained a high level of activity during the period of treatment. In contrast, the blastogenesis of PBL with PHA decreased from the first week. Suppressor cell activity was augmented from the first week and maintained throughout this period. As to clinical effect, two patients who had metastatic liver tumors showed a response to the administration of ReIFN-gamma.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age

Related Publications

J Yamada, and N Tanaka, and S Kamitani, and K Goto, and J Gangi, and K Orita
March 1984, Nagoya journal of medical science,
J Yamada, and N Tanaka, and S Kamitani, and K Goto, and J Gangi, and K Orita
February 1984, Nihon Kyobu Shikkan Gakkai zasshi,
J Yamada, and N Tanaka, and S Kamitani, and K Goto, and J Gangi, and K Orita
June 1989, Journal of biochemistry,
J Yamada, and N Tanaka, and S Kamitani, and K Goto, and J Gangi, and K Orita
May 1988, Japanese journal of cancer research : Gann,
J Yamada, and N Tanaka, and S Kamitani, and K Goto, and J Gangi, and K Orita
March 1986, Journal of immunology (Baltimore, Md. : 1950),
J Yamada, and N Tanaka, and S Kamitani, and K Goto, and J Gangi, and K Orita
June 1991, Lymphokine and cytokine research,
J Yamada, and N Tanaka, and S Kamitani, and K Goto, and J Gangi, and K Orita
January 1983, Journal of biological response modifiers,
J Yamada, and N Tanaka, and S Kamitani, and K Goto, and J Gangi, and K Orita
February 1988, Drug design and delivery,
J Yamada, and N Tanaka, and S Kamitani, and K Goto, and J Gangi, and K Orita
November 1984, Casopis lekaru ceskych,
J Yamada, and N Tanaka, and S Kamitani, and K Goto, and J Gangi, and K Orita
June 1987, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!